Current investigations into retatrutide, a dual agonist for GLP-1 and GIP receptors, are showing promising effects in addressing excess mass and diabetes 2 condition. Preclinical information suggest a novel action https://shopretatrutidepeptide.com/2026/03/12/what-is-retatrutide-peptide/